Early COVID-Related pandemic impacts and subsequent opioid outcomes among persons receiving medication for opioid use disorder: a secondary data analysis of a Type-3 hybrid trial.
Early COVID-Related pandemic impacts and subsequent opioid outcomes among persons receiving medication for opioid use disorder: a secondary data analysis of a Type-3 hybrid trial.
复制标题
DOI：
10.1186/s13722-023-00409-7
复制
发表时间：
2023-09-13
影响因子：
3.7
通讯作者：
Becker, Sara J.
中科院分区：
文献类型：
--
作者：
Janssen, Tim;Garner, Bryan R.;Yermash, Julia;Yap, Kimberly R.;Becker, Sara J.
自新冠肺炎大流行开始以来，阿片类药物过量持续增加。新冠肺炎大流行影响阿片类药物使用轨迹和阿片类药物相关问题的途径在很大程度上尚不清楚。使用流行病-大流行影响清单(EPII)，这是一种评估跨多个生命领域的大流行相关影响的新工具，我们检验了这样的假设，即大流行最初几个月经历的与COVID相关的影响(例如，人际冲突、就业、感染暴露和情绪健康)将预测阿片类药物使用的变化和后续阿片类药物相关问题。这一分析纳入了一项群组随机化的第三类实施-有效性混合试验，该试验在大流行开始之前招募了八种阿片类药物治疗的188名患者。参与者最近都接受了阿片类药物使用障碍的药物治疗，并正在积极接受治疗。参与者在基线和3个月、6个月和9个月的基线后评估中报告了他们的阿片类药物使用和阿片类药物相关问题。在2020年5月至8月期间，参与者收到了完成EPII的可选邀请。133名受访者完成了EPII，并有足够的数据分析EPII和至少一次后续跟踪。在对协变量进行调整的Logistic和零膨胀负二项分析中，在人际冲突领域中，每一次认可的大流行影响与认可任何阿片类药物使用的几率增加67%相关，在就业和感染暴露领域中的每一影响分别与认可的阿片类药物相关问题的数量增加25%和75%相关。减轻大流行对患者人际关系和就业的影响，并在阿片类药物治疗计划中促进更好的感染控制，可以防止阿片类药物相关的负面结果。试验登记本研究描述了对先前登记的临床试验的二次数据分析：ClinicalTrials.gov/ct2/show/NCT03931174。网上版载有补充材料，可在10.1186/s13722-023-00409-7查阅。
Opioid overdoses have continued to increase since the start of the COVID-19 pandemic. The pathways through which the COVID-19 pandemic has affected trajectories of opioid use and opioid-related problems are largely unknown. Using the Epidemic-Pandemic Impacts Inventory (EPII), a novel instrument that assess pandemic-related impacts across multiple life domains, we tested the hypothesis that COVID-related impacts (on e.g., interpersonal conflict, employment, infection exposure, and emotional health) experienced in the early months of the pandemic would predict changes in opioid use and opioid-related problems at follow-up. This analysis was embedded within a cluster randomized type 3 implementation-effectiveness hybrid trial that had enrolled 188 patients across eight opioid treatments prior to the start of the pandemic. Participants had all been recently inducted on medication for opioid use disorder and were actively receiving treatment. Participants reported on their opioid use and opioid-related problems at baseline and 3-, 6-, and 9-month post-baseline assessments. Between May and August 2020, participants were sent an optional invitation to complete the EPII. One hundred thirty-three respondents completed the EPII and 129 had sufficient data to analyze the EPII and at least one subsequent follow-up. In logistic and zero-inflated negative binomial analyses adjusting for covariates, each endorsed pandemic impact in the interpersonal conflict domain was associated with 67% increased odds of endorsement of any opioid use, and each impact in the employment and infection exposure-domains was associated with 25% and 75% increases in number of endorsed opioid-related problems, respectively. Mitigating the effect of the pandemic on patients’ interpersonal relationships and employment, and promoting greater infection control in opioid treatment programs, could be protective against negative opioid-related outcomes. Trial registration The present study describes secondary data analysis on a previously registered clinical trial: clinicaltrials.gov/ct2/show/NCT03931174. The online version contains supplementary material available at 10.1186/s13722-023-00409-7.
登录
查看更多内容
影响因子：
3.4
作者：
Atkins, David C.;Baldwin, Scott A.;Neighbors, Clayton
通讯作者：
Neighbors, Clayton
影响因子：
3.7
作者：
Becker SJ;Murphy CM;Hartzler B;Rash CJ;Janssen T;Roosa M;Madden LM;Garner BR
通讯作者：
Garner BR
在美国与流行流行有关的库存的分析相关的经验：与社会心理功能的联系。
影响因子：
3.1
作者：
Grasso DJ;Briggs-Gowan MJ;Carter AS;Goldstein BL;Ford JD
通讯作者：
Ford JD
DOI：
10.3122/jabfm.2017.04.170112
发表时间：
2017-07-01
影响因子：
2.9
作者：
Davis, Matthew A.;Lin, Lewei A.;Sites, Brian D.
通讯作者：
Sites, Brian D.
影响因子：
4.2
作者：
Nalven, Tessa;Spillane, Nichea S.;Schick, Melissa R.
通讯作者：
Schick, Melissa R.